Last updated 9 days ago

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

300 patients around the world
Available in Spain, Colombia, United States
Merck Sharp & Dohme LLC
1Research sites
300Patients around the world
This study is for people with
Myeloproliferative syndromes
Essential thrombocythemia
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Oncomédica - IMAT - Montería
Recruiting
Carrera 6 # 72 – 34 - Montería
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy